Targeting IL-13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years.

MLA

Guttman-Yassky, Emma, et al. “Targeting IL-13 with Tralokinumab Normalizes Type 2 Inflammation in Atopic Dermatitis Both Early and at 2 Years.” Allergy, vol. 79, no. 6, June 2024, pp. 1560–72. EBSCOhost, https://doi.org/10.1111/all.16108.

APA

Guttman-Yassky, E., Kabashima, K., Staumont-Salle, D., Nahm, W. K., Pauser, S., Da Rosa, J. C., Martel, B. C., Madsen, D. E., Røpke, M., Arlert, P., Steffensen, L., Blauvelt, A., & Reich, K. (2024). Targeting IL-13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years. Allergy, 79(6), 1560–1572. https://doi.org/10.1111/all.16108

Chicago

Guttman-Yassky, Emma, Kenji Kabashima, Delphine Staumont-Salle, Walter K Nahm, Sylvia Pauser, Joel Correa Da Rosa, Britta Cathrina Martel, et al. 2024. “Targeting IL-13 with Tralokinumab Normalizes Type 2 Inflammation in Atopic Dermatitis Both Early and at 2 Years.” Allergy 79 (6): 1560–72. doi:10.1111/all.16108.